Ribera Josep-Maria, Morgades Mireia, Montesinos Pau, Martino Rodrigo, Barba Pere, Soria Beatriz, Bermúdez Arancha, Moreno María-José, González-Campos José, Vives Susana, Gil Cristina, Abella Eugenia, Guàrdia Ramon, Martínez-Carballeira Daniel, Martínez-Sánchez Pilar, Amigo María-Luz, Mercadal Santiago, Serrano Alfons, López-Martínez Aurelio, Vall-Llovera Ferran, Sánchez-Sánchez María-José, Peñarrubia María-Jesús, Calbacho María, Méndez Jose-Angel, Bergua Juan, Cladera Antonia, Tormo Mar, García-Belmonte Daniel, Feliu Evarist, Ciudad Juana, Orfao Alberto
a ICO Badalona-Hospital Germans Trias i Pujol , Josep Carreras Leukemia Research Institute, Universitat Autònoma de Barcelona , Badalona , Spain.
b Hospital Universitari i Politècnic La Fe , Valencia , Spain.
Leuk Lymphoma. 2018 Jul;59(7):1634-1643. doi: 10.1080/10428194.2017.1397661. Epub 2017 Nov 22.
Native or pegylated (PEG) asparaginase (ASP) are commonly used in treatment of acute lymphoblastic leukemia (ALL), but have been scarcely compared in the same trial in adult patients. Native vs. PEG-ASP administered according to availability in each center were prospectively evaluated in adults with high-risk ALL. Ninety-one patients received native ASP and 35 PEG-ASP in induction. No significant differences were observed in complete remission, minimal residual disease levels after induction and after consolidation, disease-free survival, and overall survival. No significant differences in grades 3-4 toxicity were observed in the induction period, although a trend for higher hepatic toxicity was observed in patients receiving PEG-ASP. In this trial the type of ASP did not influence patient response and outcome.
天然型或聚乙二醇化（PEG）天冬酰胺酶（ASP）常用于治疗急性淋巴细胞白血病（ALL），但在成年患者的同一试验中很少进行比较。根据各中心的可获得性，对高危ALL成年患者前瞻性地评估了天然型与PEG-ASP。91例患者在诱导期接受天然型ASP，35例接受PEG-ASP。在完全缓解、诱导和巩固后的微小残留病水平、无病生存期和总生存期方面未观察到显著差异。诱导期3-4级毒性无显著差异，尽管接受PEG-ASP的患者肝毒性有升高趋势。在该试验中，ASP的类型不影响患者的反应和结局。
